For the quarter ending 2026-03-31, MIST had -$23,100K decrease in cash & cash equivalents over the period. $20,187K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Accounts payable and accrued liabilities | - | 1,273 | 1,213 |
| Net loss | 19,583 | -11,922 | -33,727 |
| Depreciation of property and equipment | -24 | 25 | 55 |
| Amortization of debt costs | -200 | 109 | 208 |
| Accretion of investment discount | - | 0 | -81 |
| Non-cash interest expense related to senior secured convertible note | -1,653 | 859 | 1,678 |
| Non-cash interest expense related to royalty financing obligation | 3,133 | - | - |
| Share-based compensation expense | -2,627 | 1,250 | 2,659 |
| Accounts receivable, net | 1,605 | - | - |
| Other receivables | 569 | -224 | -566 |
| Research and development tax credits receivable | 202 | -271 | 178 |
| Prepaid expenses | -1,332 | 1,829 | -1,092 |
| Inventory | 1,178 | - | - |
| Operating lease assets and liabilities | -2 | -8 | -3 |
| Accounts payable | 4,378 | - | - |
| Accrued liabilities | 1,836 | - | - |
| Deferred revenue | 416 | - | - |
| Net cash used in operating activities | 20,213 | -9,748 | -26,518 |
| Acquisition of property and equipment | 26 | 2 | 17 |
| Acquisition of short-term investments | 44,081 | 34,982 | 922 |
| Redemption of short-term investments | - | 0 | -44,466 |
| Net cash (used in) provided by investing activities | -88,573 | -34,984 | 43,527 |
| Proceeds from exercise of options | - | 122 | 36 |
| Proceeds from royalty financing arrangement | 75,000 | - | - |
| Proceeds from issuance of common shares, net of issuance costs | -12,253 | 23,143 | - |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | - | -2,573 | - |
| Proceeds from issuance of common stock warrants, net of issuance costs-Seriesa Common Warrants | - | 9,504 | - |
| Proceeds from issuance of common stock warrants, net of issuance costs-Seriesb Common Warrants | - | 13,416 | - |
| Proceeds from exercise of series a warrants, net of issuance costs | 8,291 | - | - |
| Proceeds from employee stock purchase plan | -116 | 160 | 140 |
| Payment of property and equipment financing | 11 | - | - |
| Cash provided by financing activities | 45,260 | 48,918 | 176 |
| Net (decrease) increase in cash and cash equivalents | -23,100 | 4,186 | 17,185 |
| Cash and cash equivalents - beginning of period | 46,685 | 25,314 | - |
| Cash and cash equivalents - end of period | 71,317 | 46,685 | - |
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)